2018
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis
Vuong H, Ho A, Altibi A, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer 2018, 123: 76-82. PMID: 30089599, DOI: 10.1016/j.lungcan.2018.07.006.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMET exonCell lung cancerAdvanced non-small cell lung cancerLung cancerGenetic eventsOdds ratioPulmonary sarcomatoid carcinomaMeta-analysisConfidence intervalsC-Met inhibitorsRandom-effects modelSarcomatoid carcinomaPrognostic featuresClinicopathological profileDismal survivalTargeted therapyClinicopathological implicationsGenomic alterationsAdvanced ageWeb of ScienceC-MetNon-smokersRare mutationsPatients
2017
Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations—a meta-analysis
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Tran H, Oishi N, Mochizuki K, Nakazawa T, Hassell L, Katoh R, Kondo T. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations—a meta-analysis. Tumor Biology 2017, 39: 1010428317713913. PMID: 29037127, DOI: 10.1177/1010428317713913.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerTERT promoter mutationsDistant metastasisThyroid cancerPromoter mutationsRET/PTC rearrangementsBRAF mutationsPresence of distant metastasesAssessment of patient prognosisTumor risk stratificationAssociated with distant metastasisPapillary thyroid carcinomaMeta-analysisPredicting distant metastasisAssociation of BRAFRandom-effects modelThyroid carcinomaTERT promoterRisk stratificationPatient prognosisRAS mutationsAdverse outcomesMetastasisIncreased riskBRAFTERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Chan A, Park C, Fung K, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data. Critical Reviews In Oncology/Hematology 2017, 120: 1-9. PMID: 29198322, DOI: 10.1016/j.critrevonc.2017.09.013.Peer-Reviewed Original ResearchConceptsTelomerase reverse transcriptase promoter mutationTelomerase reverse transcriptaseIsocitrate dehydrogenase mutation statusProgression-free survivalTERT promoter mutationsIsocitrate dehydrogenase mutationPromoter mutationsIDH-mutantGlioma patientsOverall survivalTumor gradeMutation statusTelomerase reverse transcriptase mutationsAssociated with reduced OSGrade II/III tumorsWHO grade IIMeta-analysisIDH-wild typeInverse variance methodRandom-effects modelII/III tumorsTERT-mutIII tumorsPrognostic factorsPrognostic valuePrognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis
Vuong H, Altibi A, Duong U, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis. Clinical Endocrinology 2017, 87: 411-417. PMID: 28666074, DOI: 10.1111/cen.13413.Peer-Reviewed Original ResearchConceptsTERT promoter mutationsPapillary thyroid carcinomaPromoter mutationsRisk stratificationRisk stratification of papillary thyroid carcinomaAssociated with increased tumor aggressivenessManagement of papillary thyroid carcinomaGroup of papillary thyroid carcinomasPapillary thyroid carcinoma patientsPooled estimates of odds ratiosCombination of BRAFEstimates of odds ratiosRandom-effects modelCoexisting BRAFThyroid carcinomaPrognostic implicationsTumor aggressivenessClinicopathological implicationsBRAFClinical managementConcurrent BRAFRisk groupsOdds ratioVirtual Health LibraryWeb of Science
2016
The changing characteristics and molecular profiles of papillary thyroid carcinoma over time - a systematic review
Vuong H, Altibi A, Abdelhamid A, Ngoc P, Quan V, Tantawi M, Elfil M, Le Huy Vu T, Elgebaly A, Oishi N, Nakazawa T, Hirayama K, Katoh R, Huy N, Kondo T. The changing characteristics and molecular profiles of papillary thyroid carcinoma over time - a systematic review. Oncotarget 2016, 5: 10637-10649. PMID: 27793009, PMCID: PMC5354688, DOI: 10.18632/oncotarget.12885.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorCarcinoma, PapillaryChi-Square DistributionFemaleGene RearrangementGenes, rasGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationPhenotypeProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-retRisk FactorsThyroid Cancer, PapillaryThyroid NeoplasmsTime FactorsTranscriptomeConceptsPapillary thyroid carcinomaMolecular profilingThyroid carcinomaClinicopathological featuresGenetic alterationsRisk factors of thyroid cancerPapillary thyroid carcinoma patientsSystematic reviewSurgical time periodStudent's t-testTumorigenesis of papillary thyroid carcinomaRET/PTC rearrangementsModification of patientsPearson chi-squareTeam of reviewersClinicopathological characteristicsPTC patientsBRAF mutationsThyroid cancerRAS mutationsScreened titlesRisk factorsInclusion criteriaElectronic databasesPotential articles